|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1201 Pennsylvania Ave N.W. |
Address2 | Suite 540 |
City | Washington |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 1331-12
|
||||||||
|
6. House ID# 303290000
|
TYPE OF REPORT | 8. Year | 2022 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Shawn Friesen |
Date | 1/20/2023 12:16:48 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Lobby members of Congress regarding issues related to telemedicine.
Advocate for increased transparency regarding drug pricing.
Advocate for reducing barriers to entry of generic drugs into the marketplace.
Advocate for transparency on the part of pharmaceutical benefit managers.
Advocate for patient access to compounded medications.
Advocate for reducing the burdens of utilization management tools, including step therapy and prior authorization for pharmaceuticals and services.
Advocate for a stable supply of medications and mitigate drug shortages.
Lobby members of the House to join the Congressional Skin Cancer Caucus.
Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks.
Support H. Res 436, sense of the House supporting state, local and community initiatives to curb incidences of skin cancer beginning with childhood skin cancer.
Support H. Res 718, designating October 17, 2021 as National Vitiligo Awareness Day
Support H.R. 2163/S. 464, Safe Step Act.
Support S. 989, Ensuring Childrens Access to Specialty Care Act
Support H.R. 153, Protecting Consumer Access to Generic Drugs Act
Support S. 898, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act
Support H.R. 3662, Patient Access to Urgent-Use Pharmacy Compounding Act
Support H.R. 1916/S. 754, Ensuring Lasting Smiles Act
Advocate for relief from prior authorization requirements under Medicare Advantage and Medicare Part D plans.
Advocate for the continued and increased funding of Community Health Centers.
Advocate for implementation of surprise medical billing legislation (enacted as part of P.L. 116-260, Consolidated Appropriations Act, 2021, H.R. 133) as intended by Congress.
Support H.R. 1677/S. 620, the KEEP Telehealth Options Act.
Support H.R. 2903/S. 1512 the CONNECT for Health Act of 2021
Support the Dr. Lorna Breen Health Care Provider Protection Act (S. 610/H.R. 1667).
Support H.R. 3173/S. 3018, Improving Seniors Timely Access to Care Act of 2021
Support H.R. 8437, the Improving Seniors Timely Access to Care Act of 2022
Support H.R. 4122/S. 3645, Resident Education Deferred Interest Act or the REDI Act
Support the Resident Physician Shortage Reduction Act (S. 834/H.R. 2256)
Advocate for the FDA to implement the 2015 rule, General and Plastic Surgery Devices: Restricted Sale, Distribution, and Use of Sunlamp Products; and the Sunlamp Products Proposed; Amendment to Performance Standard, which would ban minors under the age of 18 from using tanning beds.
Support H.R. 5054, Keep Physicians Serving Patients Act
Support H.R. 5394, the Meaningful Access to Federal Health Plan Claims Data Act
Advocate for legislative solution to access problems to iPLEDGE/REMS program for isotretinoin (H.R. 7667, Food and Drug Amendments of 2022/S. 4348 FDASLA Act of 2022, H.R. 2617, Consolidated Appropriations Act).
Support H.R. 7649, a bill to direct the Secretary of Health and Human Services to open a public docket for the submission of public comments regarding factors that should be taken into consideration when reviewing a proposed modification to an approved risk evaluation and mitigation strategy, and for other purposes.
Support H.R. 5030/S. 2706, the Diversifying Investigations and Equitable Research Studies for Everyone (DIVERSE) Trials Act
Support H.R. 7995, GOLD CARD Act of 2022
Advocate to provide relief from the 2% Medicare sequester, replace scheduled and anticipated cuts in payments with positive, inflationary-based updates, eliminate the nearly 4.5% conversion factor cut in the CMS proposed rule for the 2023 Medicare Physician Fee Schedule (MPFS) associated with budget neutrality adjustments tied to Evaluation & Management (E/M) Code MPFS policy changes, and waive the 4% PAYGO sequester to Medicare physician payment reimbursement due to enactment of H.R. 1319, American Recovery Act, P.L. 117-2 (H.R. 2617, Consolidated Appropriations Act).
Support H.R. 8800, Supporting Medicare Providers Act of 2022
Advocate against H.R 6708, Improving Access to Workers Compensation for Injured Federal Workers Act, which expands the role of nurse practitioners and physician assistants in providing services to injured federal workers under the federal workers' compensation program.
Oppose H.R. 8812, the Improving Care & Access to Nurses Act (I CAN Act)
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Friesen |
|
|
|
Christine |
O'Connor |
|
|
|
Jennifer |
Mangone |
|
|
|
Nicholas |
Beek |
|
|
|
Karry |
La Violette |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Advocate for medical research and prevention funding for the National Institutes of Health and Centers for Disease Control and Prevention via the FY2023 Labor, Health and Human Services, Education and Related Agencies Appropriations bill (H.R. 8295, H.R. 2617)).
Support H.R. 5030/S. 2706, the Diversifying Investigations and Equitable Research Studies for Everyone (DIVERSE) Trials Act
Advocate for Defense Health Research Programs (CDMRP) in the FY23 Defense Appropriations Act, specifically the Melanoma Research Program (MRP) (H.R. 8236, H.R. 2617).
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Friesen |
|
|
|
Christine |
O'Connor |
|
|
|
Jennifer |
Mangone |
|
|
|
Nicholas |
Beek |
|
|
|
Karry |
La Violette |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Advocate for adequate and accurate network coverage for dermatologic care within Medicare Advantage.
Advocate for increased funding and reforms to Graduate Medical Education.
Lobby members of Congress regarding improvements to Health Information Technology implementation.
Advocate for expansion of telemedicine services under Medicare and increased reimbursement for such services.
Advocate for improving disease management and care coordination for patients with chronic diseases.
Support preservation of the In-Offices Ancillary Services Exemption (IOASE) under Stark Law regarding physician self-referral and oppose repeal of the in-office ancillary and physician services exception.
Advocate for relief from Medicare regulations under Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110), including the Quality Payment Program (QPP) and specifically the development of advanced alternative payment models (APMs) and implementation of the Merit-Based Incentive Payment System (MIPS).
Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans.
Lobby Congress to urge CMS to strengthen Qualified Clinical Data Registries (QCDRs) by removing barriers that restrict access to data from EHRs. (H.R. 6000)
Advocate for congressional action to hold health care professionals harmless from any cuts related to CMS Evaluation and Management Code proposals in any forthcoming legislative package.
Support the Knowing the Efficiency and Efficacy of Permanent (KEEP) Telehealth Options Act (H.R. 1677/S. 620).
Support H.R.8437, the Improving Seniors Timely Access to Care Act of 2022
Support H.R. 3173/S. 3018, Improving Seniors Timely Access to Care Act of 2021
Support H.R. 2903/S. 1512 the CONNECT for Health Act of 2021
Support H.R. 5054, Keep Physicians Serving Patients Act
Advocate to support extension of moratorium on 2% Medicare sequester, replace scheduled and anticipated cuts in payments with positive, inflationary-based updates, eliminate the nearly 4.5% conversion factor cut in the CMS proposed rule for the 2023 Medicare Physician Fee Schedule (MPFS) associated with budget neutrality adjustments tied to Evaluation & Management (E/M) Code MPFS policy changes, and waive the 4% PAYGO sequester to Medicare physician payment reimbursement due to enactment of H.R. 1319, American Recovery Act, P.L. 117-2 (H.R. 2617, Consolidated Appropriations Act).
Support H.R. 8800, the Supporting Medicare Providers Act of 2022
Support H.R. 5394, the Meaningful Access to Federal Health Plan Claims Data Act
Support H.R. 7995, GOLD CARD Act of 2022
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Friesen |
|
|
|
Christine |
O'Connor |
|
|
|
Jennifer |
Mangone |
|
|
|
Nicholas |
Beek |
|
|
|
Karry |
La Violette |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Support the Eliminating Provider Relief Fund Tax Penalties Act of 2021 (H.R. 2079).
Oppose the Tanning Tax Repeal Act (H.R. 5642)
Support the Indian Health Service Health Professions Tax Fairness Act (S. 2874)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Friesen |
|
|
|
Christine |
O'Connor |
|
|
|
Jennifer |
Mangone |
|
|
|
Nicholas |
Beek |
|
|
|
Karry |
La Violette |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Lobby members of Congress to implement oversight of the FDA regarding the importance of sunscreen use during the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products.
Advocate for a stable supply of medications and mitigate drug shortages.
Advocate for increased transparency regarding drug pricing.
Advocate for reducing barriers to entry of generic drugs into the marketplace.
Advocate for transparency on the part of pharmaceutical benefit managers.
Advocate for patient access to compounded medications.
Advocate for reducing the burdens of utilization management tools, including step therapy and prior authorization for pharmaceuticals.
Support S. 898, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act
Support H.R. 3662, Patient Access to Urgent-Use Pharmacy Compounding Act
Advocate for legislative solution to access problems to iPLEDGE/REMS program for isotretinoin (H.R. 7667, Food and Drug Amendments of 2022/S. 4348 FDASLA Act of 2022, H.R. 2617, Consolidated Appropriations Act).
Support H.R. 7649, a bill to direct the Secretary of Health and Human Services to open a public docket for the submission of public comments regarding factors that should be taken into consideration when reviewing a proposed modification to an approved risk evaluation and mitigation strategy, and for other purposes.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Friesen |
|
|
|
Christine |
O'Connor |
|
|
|
Jennifer |
Mangone |
|
|
|
Nicholas |
Beek |
|
|
|
Karry |
La Violette |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Lobby members of Congress to implement oversight of the FDA regarding the importance of sunscreen use during the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products.
Advocate for a stable supply of medications and mitigate drug shortages.
Advocate for increased transparency regarding drug pricing.
Advocate for reducing barriers to entry of generic drugs into the marketplace.
Advocate for transparency on the part of pharmaceutical benefit managers.
Advocate for patient access to compounded medications.
Advocate for reducing the burdens of utilization management tools, including step therapy and prior authorization for pharmaceuticals.
Support S. 898, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act
Support H.R. 3662, Patient Access to Urgent-Use Pharmacy Compounding Act
Advocate for legislative solution to access problems to iPLEDGE/REMS program for isotretinoin (H.R. 7667, Food and Drug Amendments of 2022/S. 4348 FDASLA Act of 2022, H.R. 2617, Consolidated Appropriations Act).
Support H.R. 7649, a bill to direct the Secretary of Health and Human Services to open a public docket for the submission of public comments regarding factors that should be taken into consideration when reviewing a proposed modification to an approved risk evaluation and mitigation strategy, and for other purposes.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Friesen |
|
|
|
Christine |
O'Connor |
|
|
|
Jennifer |
Mangone |
|
|
|
Nicholas |
Beek |
|
|
|
Karry |
La Violette |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ENV
16. Specific lobbying issues
Advocate for the importance of sunscreen use in policies regarding the environmental impact of sunscreen ingredients, including the effect on coral reef, and any directive calling for a study by the Environmental Protection Agency and/or the National Academy of Sciences.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Friesen |
|
|
|
Christine |
O'Connor |
|
|
|
Jennifer |
Mangone |
|
|
|
Nicholas |
Beek |
|
|
|
Karry |
La Violette |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TOR
16. Specific lobbying issues
Support for the Good Samaritan Health Professionals Act (H.R. 5239/ S. 2941), which would provide medical professionals with a limited, but consistent, level of legal protection while volunteering during federally-declared disasters.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Friesen |
|
|
|
Christine |
O'Connor |
|
|
|
Jennifer |
Mangone |
|
|
|
Nicholas |
Beek |
|
|
|
Karry |
La Violette |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |